Apr. 28 at 2:51 PM
$SPRO I do find it odd behavior to (1) not hold an earnings call since May 2025; (2) indicate you will no longer update cash runway guidance (current guidance uses
$40.3M year end cash balance and doesn't contemplate any further milestones even the
$25 mln received in February); (3) request a share authorization for 240 mln common shares and 10 mln preferred shares when you currently have 120 mln authorized and only 57 mln o/s (and 12 mln more committed to the stock incentive plan -- the 2026 stock incentive plan doesn't add new shares, just retains shares available from 2017 plan and extends its expiration).
And then go completely silent on social until last week w/ images suggesting neither the CEO/CFO or corporate counsel attended -- which is kind of weird for a company of about 20 employees (key tebi clinician left in February).
I suppose you could still have dual track:
$GSK tender offer w/ no shareholder vote and AGM planned June 23 post PDUFA just in case.
